85 related articles for article (PubMed ID: 24647891)
21. Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK.
Gick U; Rochlitz C; Mingrone W; Pestalozzi B; Rauch D; Ballabeni P; Lanz D; Hess V; Aebi S
Oncology; 2006; 71(1-2):54-60. PubMed ID: 17344671
[TBL] [Abstract][Full Text] [Related]
22. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
24. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group.
Hamaker ME; Seynaeve C; Wymenga AN; van Tinteren H; Nortier JW; Maartense E; de Graaf H; de Jongh FE; Braun JJ; Los M; Schrama JG; van Leeuwen-Stok AE; de Groot SM; Smorenburg CH
Breast; 2014 Feb; 23(1):81-7. PubMed ID: 24314824
[TBL] [Abstract][Full Text] [Related]
25. First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
Debled M; Madranges N; Trainaud A; Floquet A; Donamaria C; Brouste V; Durand M; Mauriac L
Oncology; 2009; 77(5):318-27. PubMed ID: 19940523
[TBL] [Abstract][Full Text] [Related]
26. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
Yamamoto D; Iwase S; Yoshida H; Kuroda Y; Yamamoto C; Kitamura K; Odagiri H; Nagumo Y
Anticancer Res; 2010 Sep; 30(9):3827-31. PubMed ID: 20944178
[TBL] [Abstract][Full Text] [Related]
28. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Lang I; Inbar MJ; Kahán Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Messinger D; Brodowicz T; Zielinski C
Eur J Cancer; 2012 Nov; 48(17):3140-9. PubMed ID: 22640829
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.
Chitapanarux I; Kamnerdsupaphon P; Tharavichitkul E; Lorvidhaya V; Trakultivakorn H; Srisukho S; Somwangprasert A; Watcharachan K; Sukthomya V
Asia Pac J Clin Oncol; 2012 Mar; 8(1):76-82. PubMed ID: 22369447
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH
Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117
[TBL] [Abstract][Full Text] [Related]
31. Role of capecitabine (Xeloda) in breast cancer.
Kaklamani VG; Gradishar WJ
Expert Rev Anticancer Ther; 2003 Apr; 3(2):137-44. PubMed ID: 12722873
[TBL] [Abstract][Full Text] [Related]
32. Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.
O'Shaughnessy JA; Blum JL
Clin Breast Cancer; 2006 Apr; 7(1):42-50. PubMed ID: 16764743
[TBL] [Abstract][Full Text] [Related]
33. Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.
Kellokumpu-Lehtinen PL; Tuunanen T; Kautio AL; Lehtinen I; Tanner M
Anticancer Res; 2013 Nov; 33(11):4941-5. PubMed ID: 24222133
[TBL] [Abstract][Full Text] [Related]
34. [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Moiseenko VM; O'Reilly SM; Dalbot DC; Van Belle S; Gordon RJ; Griffin T; Osterwalder B
Vopr Onkol; 2000; 46(3):285-9. PubMed ID: 10976273
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
[TBL] [Abstract][Full Text] [Related]
37. Is capecitabine efficacious in triple negative metastatic breast cancer?
Kotsori AA; Dolly S; Sheri A; Parton M; Shaunak N; Ashley S; Walsh G; Johnston S; Smith IE
Oncology; 2010; 79(5-6):331-6. PubMed ID: 21430400
[TBL] [Abstract][Full Text] [Related]
38. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
O'Shaughnessy J
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 12):17-22. PubMed ID: 12435175
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma tissues and cell lines in vitro.
Loo WT; Sasano H; Chow LW
Biomed Pharmacother; 2007 Oct; 61(9):553-7. PubMed ID: 17905566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
